NeoGenomics, Inc. (NEO)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about NeoGenomics, Inc. (NEO)
Company Performance

Current Price

as of Nov 25, 2024

$16.93

P/E Ratio

N/A

Market Cap

$2.17B

Description

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Metrics

Overview

  • HQFort Myers, FL
  • SectorHealth Services
  • IndustryMedical/Nursing Services
  • TickerNEO
  • Price$16.93+3.29%

Trading Information

  • Market cap$2.17B
  • Float98.78%
  • Average Daily Volume (1m)756,038
  • Average Daily Volume (3m)749,908
  • EPS-$0.62

Company

  • Revenue$644.12M
  • Rev growth (1yr)10.44%
  • Net income-$17.70M
  • Gross margin42.56%
  • EBITDA margin-1.31%
  • EBITDA-$2.20M
  • EV$2.09B
  • EV/Revenue3.25
  • P/EN/A
  • P/S3.34
  • P/B2.39